Talk:GT-02287

This is the talk page for discussing improvements to the GT-02287 article.
This is not a forum for general discussion of the subject of the article.

Add new text under old text.
New to Wikipedia? Welcome! Learn to edit; get help.

Start a new topic

Article policies

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

Pharmacology

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
???	This article has not yet received a rating on the project's importance scale.

Chemicals

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals
???	This article has not yet received a rating on the project's importance scale.

Proposed edits to GT-02287 page

Latest comment: 14 days ago1 comment1 person in discussion

I am affiliated with Gain Therapeutics. I noticed some language on this page about rexaceract - formerly known as GT-02287- that appears incorrect or outdated. I am requesting review rather than making direct edits due to my conflict of interest. Below are the statements, proposed corrections, and sources (some of which have already been cited on this page).

Current text(1): GT-02287 is a β-glucocerebrosidase (GCase) activator, positive allosteric modulator, and/or chaperone which is under development for the treatment of Parkinson's disease, Gaucher's disease, solid tumors, and dementia. It is taken orally.

Proposed edit(1): Rexaceract is a β-glucocerebrosidase (GCase) activator, positive allosteric modulator, and/or chaperonewhich is under development for the treatment of Parkinson's disease, Gaucher's disease, and dementia. It is taken orally.

Reason for correction(1): Updated with recently approved INN name. Additionally, rexaceract is not under development for solid tumors.

Source(1): https://adisinsight.springer.com/drugs/800063603

https://gaintherapeutics.com/pipeline/,

Current text (2): The drug is under development by Gain Therapeutics. As of January 2026, it is in phase 1 clinical trialsfor Parkinson's disease, the preclinical research stage of development for Gaucher's disease and solid tumors, and the research stage of development for dementia. GT-02287 was also under development for alpha 1-antitrypsin deficiency, globoid cell leukodystrophy, and GM1 gangliosidosis, but development for these indications was discontinued.

Proposed edit(2): The drug is under development by Gain Therapeutics. As of January 2026, it is in phase 1 clinical trialsfor Parkinson's disease, the preclinical research stage of development for Gaucher's disease, and the research stage of development for dementia.

Reason for correction (2): Rexaceract is not under development for solid tumors. Additionally, rexaceract was never under development for alpha 1-antitrypsin deficiency, globoid cell leukodystrophy, and GM1 gangliosidosis.

Source (2) : https://gaintherapeutics.com/pipeline/h, ttps://adisinsight.springer.com/drugs/800063603 , AJammu Gain (talk) 21:53, 29 July 2026 (UTC)Reply